secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0000950103-22-003581
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q4 net loss $25M, FY loss $96.8M; $163.7M cash; clinical progress
--------------------------------------------------------------------------

- Q4 net loss from continuing ops $25.0M ($0.13/sh) vs $39.7M ($0.22/sh) year ago; full-year net loss $96.8M ($0.49/sh) vs $103.8M.
- Cash, cash equivalents and investments totaled $163.7M as of Dec 31, 2021; net cash used in ops $55.8M in 2021, down from $77.0M in 2020.
- January 2021 public offering of 17.25M shares raised gross proceeds of ~$129.4M; cash expected to fund operations well into 2023.
- Clinical milestones: completed enrollment in PRGN-3006 AML, PRGN-3005 ovarian, and PRGN-2012 RRP studies; IND clearances for PRGN-3007 and PRGN-2012.
- R&D expenses up 20% for the year; SG&A down 19%; non-core businesses (Trans Ova, Exemplar) increased revenues and profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322003581/0000950103-22-003581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322003581/dp168191_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-22-003581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer